ASH 2024 Highlights: Early Smouldering Myeloma Treatment and Breakthrough Therapies in Multiple Myeloma Take Center Stage

Highlights from ASH 2024 include groundbreaking data from the Aquila study on high-risk smoldering myeloma. This trial revealed that early treatment with daratumumab monotherapy halved mortality rates after four years, suggesting a paradigm shift in treating early-stage myeloma. Also, new data showed that belantamab-bortezomib-dex tripled progression-free survival and halved mortality compared to daratumumab-based regimens. Promising results were also presented for a new trispecific antibody targeting CD3, CD38, and BCMA.